PCM
KNSA icon

Prelude Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Prelude Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Sell
4,594
-2,476
-35% -$110K 0.02% 863
2025
Q4 		$292K Buy
+7,070
New +$284K 0.02% 807
2019
Q3 		– Sell
-425
Closed -$6K – 1888
2019
Q2 		$6K Buy
+425
New +$6.59K ﹤0.01% 1499

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Prelude Capital Management's KNSA Position: Q1 2026 in Review

Prelude Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 35% in Q1 2026, selling an estimated $110K and leaving 4,594 shares worth $221K. The position accounts for 0.02% of the portfolio, ranked #863.

Prelude Capital Management first reported a position in KNSA in Q2 2019 and has held it in 3 quarters since. The position peaked at $292K in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Prelude Capital Management held 4,594 shares of Kiniksa Pharmaceuticals worth $221K as of Q1 2026.
  • Prelude Capital Management sold 2,476 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $110K.
  • Kiniksa Pharmaceuticals made up 0.02% of Prelude Capital Management's portfolio in Q1 2026, its #863 holding.
  • Prelude Capital Management first reported a position in Kiniksa Pharmaceuticals in Q2 2019 and has held it in 3 quarters since.
  • Prelude Capital Management's Kiniksa Pharmaceuticals position peaked at $292K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.